GSK plc vs iShares Core High Dividend ETF — how do they compare? GSK plc trades at $51.15 (market cap $102.60B), while iShares Core High Dividend ETF trades at $29.04. The key difference: GSK plc pays a 3.57% dividend while iShares Core High Dividend ETF pays none, and iShares Core High Dividend ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | HDV | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | — |
52-Week High | $61.18 | $29.14 |
52-Week Low | $38.22 | $23.64 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
HDV trades at $29.04, up 0.17% with a bullish technical signal from moving averages. The ETF focuses on high-quality dividend stocks, delivering a 3.1% yield while outperforming the S&P 500 by 9 percentage points year-to-date. Recent institutional buying includes Bay Colony Advisors increasing holdings by 370.7% and 180 Wealth Advisors by 386.2% in Q2 2026. Technical indicators show strong momentum with RSI at 76.33 suggesting overbought conditions, while support and resistance cluster around $29.
HDV offers attractive income generation through quality dividend stocks, with defensive sector exposure providing stability. The ETF's screening methodology favors companies with sustainable dividends and strong balance sheets. Key risks include interest rate sensitivity and sector concentration in healthcare and energy. Current technical overbought conditions may limit near-term upside potential despite strong institutional interest.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →